Table 4.
Overall Survival and Value of Atezolizumab and Pembrolizumab
| Drug and setting | OS gains in days/Grade(OS/g) & HR | C/LYG | RV |
|---|---|---|---|
| aAtezolizumab (Atezo) vs. Doc irrespective of PD-L1, vs. Doc (phase II, POPLAR) [8] | 87/C HR 0.73 P = 0.040 |
$618,244 | 0.16 |
| Atezo, low or undetectable PD-L1 vs. Doc, Phase III OAK [9, 10] | 111/C HR 0.75 | $475,265 | 0.21 |
| Atezo, PD-L1 > 1.0% tumor cells (TC) or in tumor-infiltrating immune cells (IC) vs. Doc [10] | 162/B HR 0.74 P = 0.0102 |
$325,644 | 0.30 |
| Atezo, PD-L1, TC or IC > 5% vs. Doc, [10] | 165/B | $319,974 | 0.31 |
| Atezo, PD-L1 > 50% or IC > 10% vs. Doc | 348/A + HR 0.41 | $151,193 | 0.66 |
| Pembrolizumab (Pembro) PD- L1 > 1.0% positive vs. Doc KEYNOTE − 010 [7] Subset analysis | 57/D HR 0.71 P = 0.0008 |
$659,059 | 0.15 |
| Pembro 10 mg/Kg, PD-L1 1.0% positive, KEYNOTE − 010 | 126/B HR 0.61 | $1,490,729 | 0.07 |
| Pembro 2.0 mg/Kg, > 50% positive KEYNOTE − 010 | 201/A HR 0.54 | $186,897 | 0.53 |
aThe average OS gains of Atezo in the POPLAR and OAK were 99 days at C/LYG of $551,407 and RV 0.19